Insider trading activities (stock purchases, sales, and option exercises)
reported by insiders of Travere Therapeutics, Inc. (TVTX)
since 2015 are shown in Table 1 and Table 2.
Table 1 shows the monthly insider trading data of Travere Therapeutics, Inc..
Table 2 shows the detailed insider transactions.
This company's CIK number is 1438533.
Total stock buying since 2015: $165,815.
Total stock sales since 2015: $27,458,794.
Total stock option exercises since 2015: $3,894,352.
Table 3. Detailed insider trading at Travere Therapeutics, Inc. (TVTX)
| Trade Date |
Insider Name |
Trade Type |
Shares |
Price ($) |
Value ($) |
| 2025-08-27 | Cline Christopher R. (CHIEF FINANCIAL OFFICER) | Sale | 470 | 17.31 | 8,135 |
| 2025-07-01 | Inrig Jula (CHIEF MEDICAL OFFICER) | Sale | 815 | 14.65 | 11,939 |
| 2025-05-05 | Cline Christopher R. (CHIEF FINANCIAL OFFICER) | Sale | 1,784 | 21.05 | 37,553 |
| 2025-05-05 | Heerma Peter (CHIEF COMMERCIAL OFFICER) | Sale | 1,771 | 21.05 | 37,279 |
| 2025-05-05 | Dube Eric M (CHIEF EXECUTIVE OFFICER) | Sale | 18,924 | 21.05 | 398,350 |
| 2025-05-05 | Rote William E. (Chief Research Officer) | Sale | 3,198 | 21.05 | 67,317 |
| 2025-05-05 | Reed Elizabeth E (Chief Legal Officer and GC) | Sale | 4,920 | 21.05 | 103,566 |
| 2025-05-02 | Cline Christopher R. (CHIEF FINANCIAL OFFICER) | Option Ex | 4,920 | .00 | 0 |
| 2025-05-02 | Heerma Peter (CHIEF COMMERCIAL OFFICER) | Option Ex | 4,920 | .00 | 0 |
| 2025-05-02 | Dube Eric M (CHIEF EXECUTIVE OFFICER) | Option Ex | 18,924 | .00 | 0 |
| 2025-05-02 | Rote William E. (Chief Research Officer) | Option Ex | 4,920 | .00 | 0 |
| 2025-05-02 | Reed Elizabeth E (Chief Legal Officer and GC) | Option Ex | 4,920 | .00 | 0 |
| 2025-04-11 | Cline Christopher R. (CHIEF FINANCIAL OFFICER) | Sale | 48 | 13.14 | 630 |
| 2025-02-12 | Inrig Jula (CHIEF MEDICAL OFFICER) | Sale | 2,568 | 23.53 | 60,425 |
| 2025-02-12 | Heerma Peter (CHIEF COMMERCIAL OFFICER) | Sale | 2,568 | 23.53 | 60,425 |
| 2025-02-12 | Rote William E. (SENIOR VICE PRESIDENT, R&D) | Sale | 5,200 | 23.53 | 122,356 |
| 2025-02-12 | Reed Elizabeth E (SVP, GC & CORPORATE SECRETARY) | Sale | 8,000 | 23.53 | 188,240 |
| 2025-02-11 | Calvin Sandra (SVP, CHIEF ACCOUNTING OFFICER) | Sale | 54,244 | 25.00 | 1,356,100 |
| 2025-02-11 | Calvin Sandra (SVP, CHIEF ACCOUNTING OFFICER) | Option Ex | 45,000 | 16.77 | 754,785 |
| 2025-02-11 | Heerma Peter (CHIEF COMMERCIAL OFFICER) | Sale | 3,074 | 25.00 | 76,850 |
| 2025-02-11 | Dube Eric M (CHIEF EXECUTIVE OFFICER) | Sale | 11,375 | 24.04 | 273,455 |
| 2025-02-10 | Inrig Jula (CHIEF MEDICAL OFFICER) | Option Ex | 8,000 | .00 | 0 |
| 2025-02-10 | Heerma Peter (CHIEF COMMERCIAL OFFICER) | Option Ex | 8,000 | .00 | 0 |
| 2025-02-10 | Rote William E. (SENIOR VICE PRESIDENT, R&D) | Option Ex | 8,000 | .00 | 0 |
| 2025-02-10 | Reed Elizabeth E (SVP, GC & CORPORATE SECRETARY) | Option Ex | 8,000 | .00 | 0 |
| 2025-02-06 | Baynes Roy D. | Sale | 10,000 | 22.00 | 220,000 |
| 2025-02-06 | Baynes Roy D. | Option Ex | 10,000 | 17.44 | 174,400 |
| 2025-02-04 | Inrig Jula (CHIEF MEDICAL OFFICER) | Sale | 1,066 | 20.11 | 21,437 |
| 2025-02-03 | Cline Christopher R. (CHIEF FINANCIAL OFFICER) | Sale | 5,192 | 20.12 | 104,463 |
| 2025-02-03 | Inrig Jula (CHIEF MEDICAL OFFICER) | Sale | 4,207 | 20.12 | 84,644 |
| 2025-02-03 | Calvin Sandra (SVP, CHIEF ACCOUNTING OFFICER) | Sale | 3,348 | 20.12 | 67,361 |
| 2025-02-03 | Heerma Peter (CHIEF COMMERCIAL OFFICER) | Sale | 5,166 | 20.12 | 103,939 |
| 2025-02-03 | Dube Eric M (CHIEF EXECUTIVE OFFICER) | Sale | 50,691 | 20.21 | 1,024,363 |
| 2025-02-03 | Rote William E. (SENIOR VICE PRESIDENT, R&D) | Sale | 8,951 | 19.78 | 177,050 |
| 2025-02-03 | Reed Elizabeth E (SVP, GC & CORPORATE SECRETARY) | Sale | 8,951 | 19.78 | 177,050 |
| 2025-01-23 | Baynes Roy D. | Sale | 16,000 | 20.00 | 320,000 |
| 2025-01-23 | Baynes Roy D. | Option Ex | 16,000 | 17.50 | 280,000 |
| 2025-01-22 | Cline Christopher R. (CHIEF FINANCIAL OFFICER) | Sale | 865 | 18.94 | 16,383 |
| 2025-01-22 | Calvin Sandra (SVP, CHIEF ACCOUNTING OFFICER) | Sale | 925 | 18.94 | 17,520 |
| 2025-01-22 | Heerma Peter (CHIEF COMMERCIAL OFFICER) | Sale | 1,584 | 18.94 | 30,002 |
| 2025-01-22 | Dube Eric M (CHIEF EXECUTIVE OFFICER) | Sale | 10,736 | 19.46 | 208,922 |
| 2025-01-22 | Rote William E. (SENIOR VICE PRESIDENT, R&D) | Sale | 2,437 | 19.46 | 47,424 |
| 2025-01-22 | Reed Elizabeth E (SVP, GC & CORPORATE SECRETARY) | Sale | 2,437 | 19.46 | 47,424 |
| 2025-01-06 | Inrig Jula (CHIEF MEDICAL OFFICER) | Sale | 440 | 18.76 | 8,254 |
| 2025-01-03 | Inrig Jula (CHIEF MEDICAL OFFICER) | Sale | 2,066 | 19.10 | 39,460 |
| 2024-11-25 | Calvin Sandra (SVP, CHIEF ACCOUNTING OFFICER) | Sale | 12,090 | 18.30 | 221,259 |
| 2024-11-25 | Calvin Sandra (SVP, CHIEF ACCOUNTING OFFICER) | Option Ex | 15,000 | 12.67 | 190,050 |
| 2024-10-04 | Lyons Gary A | Sale | 40,000 | 14.75 | 590,040 |
| 2024-10-04 | Lyons Gary A | Option Ex | 40,000 | 10.48 | 419,200 |
| 2024-09-30 | Meckler Jeffrey A | Sale | 40,000 | 14.06 | 562,320 |
| 2024-09-30 | Meckler Jeffrey A | Option Ex | 40,000 | 10.48 | 419,200 |
| 2024-09-10 | Inrig Jula (CHIEF MEDICAL OFFICER) | Sale | 684 | 12.98 | 8,878 |
| 2024-09-09 | Cline Christopher R. (CHIEF FINANCIAL OFFICER) | Sale | 2,490 | 11.52 | 28,684 |
| 2024-09-09 | Inrig Jula (CHIEF MEDICAL OFFICER) | Sale | 2,191 | 11.52 | 25,240 |
| 2024-09-09 | Heerma Peter (CHIEF COMMERCIAL OFFICER) | Sale | 2,191 | 11.52 | 25,240 |
| 2024-09-09 | Dube Eric M (CHIEF EXECUTIVE OFFICER) | Sale | 21,125 | 11.52 | 243,360 |
| 2024-09-09 | Rote William E. (SENIOR VICE PRESIDENT, R&D) | Sale | 4,387 | 11.52 | 50,538 |
| 2024-09-09 | Reed Elizabeth E (SVP, GC & CORPORATE SECRETARY) | Sale | 4,387 | 11.52 | 50,538 |
| 2024-09-04 | Cline Christopher R. (CHIEF FINANCIAL OFFICER) | Sale | 514 | 9.51 | 4,887 |
| 2024-04-11 | Cline Christopher R. (CHIEF FINANCIAL OFFICER) | Sale | 54 | 6.74 | 363 |
| 2024-02-01 | Cline Christopher R. (CHIEF FINANCIAL OFFICER) | Sale | 3,818 | 8.53 | 32,571 |
| 2024-02-01 | Inrig Jula (CHIEF MEDICAL OFFICER) | Sale | 2,174 | 8.53 | 18,546 |
| 2024-02-01 | Calvin Sandra (SVP, CHIEF ACCOUNTING OFFICER) | Sale | 2,820 | 8.53 | 24,057 |
| 2024-02-01 | Heerma Peter (CHIEF COMMERCIAL OFFICER) | Sale | 4,195 | 8.53 | 35,787 |
| 2024-02-01 | Dube Eric M (CHIEF EXECUTIVE OFFICER) | Sale | 19,122 | 8.70 | 166,284 |
| 2024-02-01 | Rote William E. (SENIOR VICE PRESIDENT, R&D) | Sale | 4,764 | 8.70 | 41,427 |
| 2024-02-01 | Reed Elizabeth E (SVP, GC & CORPORATE SECRETARY) | Sale | 4,764 | 8.70 | 41,427 |
| 2024-01-23 | Cline Christopher R. (CHIEF FINANCIAL OFFICER) | Sale | 853 | 9.07 | 7,735 |
| 2024-01-23 | Calvin Sandra (SVP, CHIEF ACCOUNTING OFFICER) | Sale | 910 | 9.07 | 8,251 |
| 2024-01-23 | Heerma Peter (CHIEF COMMERCIAL OFFICER) | Sale | 1,559 | 9.07 | 14,137 |
| 2024-01-23 | Dube Eric M (CHIEF EXECUTIVE OFFICER) | Sale | 7,873 | 8.96 | 70,542 |
| 2024-01-23 | Rote William E. (SENIOR VICE PRESIDENT, R&D) | Sale | 2,062 | 8.96 | 18,475 |
| 2024-01-23 | Reed Elizabeth E (SVP, GC & CORPORATE SECRETARY) | Sale | 2,062 | 8.96 | 18,475 |
| 2024-01-04 | Inrig Jula (Chief Medical Officer) | Sale | 440 | 9.17 | 4,034 |
| 2024-01-03 | Inrig Jula (Chief Medical Officer) | Sale | 2,069 | 9.48 | 19,612 |
| 2023-10-03 | Heerma Peter (Chief Commercial Officer) | Sale | 3,091 | 8.25 | 25,503 |
| 2023-09-05 | Cline Christopher R. (Chief Financial Officer) | Sale | 457 | 14.71 | 6,722 |
| 2023-09-05 | Dube Eric M (Chief Executive Officer) | Sale | 4,455 | 14.71 | 65,533 |
| 2023-09-05 | Rote William E. (Senior Vice President, R&D) | Sale | 1,815 | 14.71 | 26,698 |
| 2023-09-05 | Reed Elizabeth E (SVP, GC & Corporate Secretary) | Sale | 1,815 | 14.71 | 26,698 |
| 2023-05-11 | Calvin Sandra (SVP, Chief Accounting Officer) | Sale | 122 | 16.12 | 1,966 |
| 2023-05-10 | Cline Christopher R. (Chief Financial Officer) | Sale | 455 | 16.59 | 7,548 |
| 2023-05-10 | Calvin Sandra (SVP, Chief Accounting Officer) | Sale | 436 | 16.59 | 7,233 |
| 2023-05-10 | Rote William E. (Senior Vice President, R&D) | Sale | 825 | 16.59 | 13,686 |
| 2023-05-10 | Reed Elizabeth E (SVP, GC & Corporate Secretary) | Sale | 825 | 16.59 | 13,686 |
| 2023-04-11 | Cline Christopher R. (Chief Financial Officer) | Sale | 47 | 21.49 | 1,010 |
| 2023-02-02 | Calvin Sandra (SVP, Chief Accounting Officer) | Sale | 360 | 22.42 | 8,071 |
| 2023-02-01 | Cline Christopher R. (Chief Financial Officer) | Sale | 1,588 | 21.75 | 34,542 |
| 2023-02-01 | Calvin Sandra (SVP, Chief Accounting Officer) | Sale | 1,671 | 21.75 | 36,347 |
| 2023-02-01 | Heerma Peter (Chief Commercial Officer) | Sale | 1,779 | 21.75 | 38,696 |
| 2023-02-01 | Dube Eric M (Chief Executive Officer) | Sale | 8,196 | 22.25 | 182,361 |
| 2023-02-01 | Rote William E. (Senior Vice President, R&D) | Sale | 2,590 | 22.25 | 57,627 |
| 2023-02-01 | Reed Elizabeth E (SVP, GC & Corporate Secretary) | Sale | 2,590 | 22.25 | 57,627 |
| 2022-10-04 | Heerma Peter (Chief Commercial Officer) | Sale | 3,042 | 25.68 | 78,118 |
| 2022-09-13 | Calvin Sandra (SVP, Chief Accounting Officer) | Sale | 349 | 28.00 | 9,772 |
| 2022-05-12 | Reed Elizabeth E (SVP, GC & Corporate Secretary) | Sale | 1,050 | 21.51 | 22,584 |
| 2022-05-11 | Calvin Sandra (SVP, Chief Accounting Officer) | Sale | 445 | 21.92 | 9,756 |
| 2022-05-11 | Rote William E. (Senior Vice President, R&D) | Sale | 1,563 | 21.72 | 33,953 |
| 2022-05-11 | Clague Laura (Chief Financial Officer) | Sale | 1,375 | 21.51 | 29,576 |
| 2022-05-11 | Aselage Steve (Director) | Sale | 2,575 | 21.93 | 56,456 |
| 2022-05-10 | Calvin Sandra (SVP, Chief Accounting Officer) | Sale | 436 | 21.51 | 9,378 |
| 2022-05-10 | Clague Laura (Chief Financial Officer) | Sale | 825 | 21.51 | 17,745 |
| 2022-05-10 | Reed Elizabeth E (SVP, GC & Corporate Secretary) | Sale | 900 | 21.51 | 19,359 |
| 2022-02-10 | Dube Eric M (Chief Executive Officer) | Sale | 4,832 | 27.84 | 134,522 |
| 2022-01-31 | Calvin Sandra (VP, Corp Controller and CAO) | Sale | 798 | 26.51 | 21,151 |
| 2022-01-31 | Heerma Peter (Chief Commercial Officer) | Sale | 1,125 | 27.40 | 30,825 |
| 2022-01-31 | Dube Eric M (Chief Executive Officer) | Sale | 4,813 | 27.40 | 131,876 |
| 2022-01-31 | Rote William E. (Senior Vice President, R&D) | Sale | 1,125 | 27.40 | 30,825 |
| 2022-01-31 | Clague Laura (Chief Financial Officer) | Sale | 1,238 | 27.40 | 33,921 |
| 2022-01-31 | Reed Elizabeth E (SVP, GC & Corporate Secretary) | Sale | 1,350 | 27.40 | 36,990 |
| 2022-01-24 | Calvin Sandra (VP, Corp Controller and CAO) | Sale | 934 | 24.58 | 22,954 |
| 2022-01-24 | Heerma Peter (Chief Commercial Officer) | Sale | 1,875 | 24.98 | 46,837 |
| 2022-01-24 | Dube Eric M (Chief Executive Officer) | Sale | 7,873 | 24.98 | 196,667 |
| 2022-01-24 | Rote William E. (Senior Vice President, R&D) | Sale | 1,875 | 24.98 | 46,837 |
| 2022-01-24 | Clague Laura (Chief Financial Officer) | Sale | 2,063 | 24.98 | 51,533 |
| 2022-01-24 | Reed Elizabeth E (SVP, GC & Corporate Secretary) | Sale | 2,250 | 24.98 | 56,205 |
| 2022-01-11 | Rote William E. (Senior Vice President, R&D) | Sale | 2,500 | 27.40 | 68,500 |
| 2022-01-11 | Clague Laura (Chief Financial Officer) | Sale | 7,500 | 27.40 | 205,500 |
| 2022-01-11 | Reed Elizabeth E (SVP, GC & Corporate Secretary) | Sale | 5,000 | 27.40 | 137,000 |
| 2022-01-05 | Dube Eric M (Chief Executive Officer) | Sale | 12,500 | 30.16 | 377,000 |
| 2022-01-04 | Dube Eric M (Chief Executive Officer) | Sale | 4,832 | 30.43 | 147,037 |
| 2021-11-16 | Aselage Steve (Director) | Sale | 31,800 | 29.39 | 934,602 |
| 2021-11-05 | Aselage Steve (Director) | Sale | 10,000 | 26.23 | 262,300 |
| 2021-11-05 | Aselage Steve (Director) | Option Ex | 10,000 | 16.23 | 162,300 |
| 2021-11-02 | Aselage Steve (Director) | Sale | 3,500 | 30.00 | 105,000 |
| 2021-11-01 | Aselage Steve (Director) | Sale | 5,000 | 29.48 | 147,400 |
| 2021-10-07 | Aselage Steve (Director) | Sale | 60,000 | 26.25 | 1,574,700 |
| 2021-10-07 | Aselage Steve (Director) | Option Ex | 60,000 | 16.23 | 973,800 |
| 2021-10-04 | Heerma Peter (Chief Commercial Officer) | Sale | 3,058 | 24.77 | 75,746 |
| 2021-08-17 | Heerma Peter (Chief Commercial Officer) | Sale | 1,407 | 17.12 | 24,086 |
| 2021-08-17 | Dube Eric M (Chief Executive Officer) | Sale | 7,836 | 17.12 | 134,144 |
| 2021-08-17 | Rote William E. (Senior Vice President, R&D) | Sale | 1,407 | 17.12 | 24,085 |
| 2021-08-17 | Rosenberg Noah L. (Chief Medical Officer) | Sale | 1,407 | 17.12 | 24,085 |
| 2021-08-17 | Clague Laura (Chief Financial Officer) | Sale | 1,407 | 17.12 | 24,085 |
| 2021-08-17 | Reed Elizabeth E (SVP, GC & Corporate Secretary) | Sale | 1,407 | 17.12 | 24,086 |
| 2021-07-28 | Rosenberg Noah L. (Chief Medical Officer) | Sale | 1,250 | 13.81 | 17,262 |
| 2021-06-02 | Dube Eric M (Chief Executive Officer) | Sale | 4,780 | 14.35 | 68,593 |
| 2021-06-01 | Dube Eric M (Chief Executive Officer) | Sale | 4,782 | 14.89 | 71,203 |
| 2021-05-12 | Rote William E. (Senior Vice President, R&D) | Sale | 1,562 | 19.46 | 30,396 |
| 2021-05-12 | Rosenberg Noah L. (Chief Medical Officer) | Sale | 375 | 19.46 | 7,297 |
| 2021-05-12 | Clague Laura (Chief Financial Officer) | Sale | 2,000 | 19.46 | 38,920 |
| 2021-05-12 | Reed Elizabeth E (SVP, GC & Corporate Secretary) | Sale | 1,625 | 19.46 | 31,622 |
| 2021-05-11 | Rote William E. (Senior Vice President, R&D) | Sale | 1,563 | 19.14 | 29,915 |
| 2021-05-11 | Rosenberg Noah L. (Chief Medical Officer) | Sale | 375 | 19.14 | 7,177 |
| 2021-05-11 | Clague Laura (Chief Financial Officer) | Sale | 2,000 | 19.14 | 38,280 |
| 2021-05-11 | Reed Elizabeth E (SVP, GC & Corporate Secretary) | Sale | 1,625 | 19.14 | 31,102 |
| 2021-05-11 | Aselage Steve (Director) | Sale | 2,146 | 19.58 | 42,022 |
| 2021-03-17 | Aselage Steve (Director) | Sale | 17,727 | 27.45 | 486,694 |
| 2021-03-17 | Aselage Steve (Director) | Option Ex | 10,000 | 16.23 | 162,300 |
| 2021-02-18 | Rote William E. (Senior Vice President, R&D) | Sale | 1,250 | 28.67 | 35,837 |
Insider trading activities including stock purchases, stock sales, and option exercises
of TVTX listed in the above tables cannot be completely guaranteed as to their accuracy.
For more insider trading information of Travere Therapeutics, Inc. (symbol TVTX,
CIK number 1438533) see
the Securities and Exchange Commission (SEC) website.